DDInter454 DDInter1376
Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Cyclobenzaprine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Cyclobenzaprine {u} (Compound) resembles {v} (Compound) Bromodiphenhydramine
Cyclobenzaprine {u} may lead to a major life threatening interaction when taken with {v} Doxepin
Cyclobenzaprine {u} (Compound) resembles {v} (Compound) Olopatadine
Cyclobenzaprine {u} (Compound) binds {v} (Gene) CYP1A2
Cyclobenzaprine {u} (Compound) palliates {v} (Disease) migraine
Cyclobenzaprine {u} (Compound) is included by {v} (Pharmacologic Class) Centrally-mediated Muscle Relaxation
Cyclobenzaprine {u} (Compound) causes {v} (Side Effect) Anxiety
Cyclobenzaprine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azatadine
Cyclobenzaprine {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Cyclobenzaprine (Compound) resembles Bromodiphenhydramine (Compound)
Cyclobenzaprine may lead to a major life threatening interaction when taken with Doxepin
Cyclobenzaprine (Compound) resembles Olopatadine (Compound)
Cyclobenzaprine (Compound) binds CYP1A2 (Gene)
Cyclobenzaprine (Compound) palliates migraine (Disease)
Cyclobenzaprine (Compound) is included by Centrally-mediated Muscle Relaxation (Pharmacologic Class)
Cyclobenzaprine (Compound) causes Anxiety (Side Effect)
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Cyclobenzaprine may lead to a major life threatening interaction when taken with Potassium chloride